1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, August 2018 (p3)

Cancer Analysis & Statistics in European Union, August 2018 (p3)

61-90 of about 100 reports

Ensartinib

Ensartinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEnsartinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Xcovery. In approximately 3–5% of all non-small cell lung cancer (NSCLC) patients, abnormal ALK ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alunbrig

Alunbrig

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. In preclinical studies, Alunbrig showed potent activity against ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Capmatinib

Capmatinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewCapmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Portrazza

Portrazza

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewPortrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Renal Cell Cancer Pricing, Reimbursement, and Access

Renal Cell Cancer Pricing, Reimbursement, and Access

  • $ 2995
  • Industry report
  • August 2018

OverviewThere is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild. Spend in RCC is among the top five oncology indications. Although payers ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Ninlaro

Ninlaro

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewNinlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways. Preclinical studies ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Ygalo

Ygalo

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewYgalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine. By utilizing peptidases that are overexpressed in malignant ...

  • Industries : Cancer
  • Countries : United States, European Union
Velcade

Velcade

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewVelcade (bortezomib; Takeda/Johnson and Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Darzalex

Darzalex

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewDarzalex (daratumumab; Johnson and Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in othe ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Kyprolis

Kyprolis

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewKyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Bladder Cancer Market and Forecast Analysis

Bladder Cancer Market and Forecast Analysis

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewBladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Acute Lymphobastic Leukemia Forecast and Market Analysis to 2024

Acute Lymphobastic Leukemia Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • July 2018

Disease OverviewAcute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

Glioblastoma Multiforme Disease (GBM) Coverage Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

DISEASE OVERVIEWGlioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023

Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • May 2018

DISEASE OVERVIEWOvarian cancer is defined as a group of tumors that originate in the ovaries. Epithelial ovarian cancer is the prevailing cause of death from gynecological malignancies in the Western world. ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

NHL: Follicular Lymphoma Forecast and Market Analysis to 2025

  • $ 22000
  • Industry report
  • April 2018

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL). It is the second most common type of NHL after diffuse large B-cell lymphoma (DLBCL), and accounts for more than 20% of ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

NHL: Mantle Cell Lymphoma Disease Coverage Forecast and Market Analysis to 2034

  • $ 22000
  • Industry report
  • April 2018

Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3–6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells ...

  • Industries : Cancer, Pathology
  • Countries : European Union, United States, Japan
NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • $ 22000
  • Industry report
  • April 2018

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Industries : Cancer, Pathology, Medical Biotechnology
  • Countries : United States, Japan, European Union
Ovarian Cancer Pricing, Reimbursement, and Access

Ovarian Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • March 2018

Ovarian cancer medicines have traditionally been subject to low restrictions, as most patients usually start and remain on inexpensive platinum-based therapies. However, beginning with the launch of vascula ...

  • Industries : Therapy
  • Countries : United States, European Union
Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • Industry report
  • January 2018

DISEASE OVERVIEWProstate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Drug Analysis: ipatasertib

Drug Analysis: ipatasertib

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewIpatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Analysis: apalutamide

Drug Analysis: apalutamide

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewApalutamide (Johnson and Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Xtandi

Drug Overview: Xtandi

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Tecentriq

Drug Analysis: Tecentriq

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Drug Analysis: Xofigo

Drug Analysis: Xofigo

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Zytiga

Drug Analysis: Zytiga

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewZytiga (abiraterone acetate; Johnson and Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Overview: Jevtana

Drug Overview: Jevtana

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewJevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Industries : Therapy
  • Countries : United States, Japan, European Union
Drug Analysis: Xtandi

Drug Analysis: Xtandi

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewXtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Drug Analysis: Rubraca

Drug Analysis: Rubraca

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewRubraca (rucaparib) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations ...

  • Industries : Therapy, Cancer, Pathology, Oncology
  • Countries : United States, European Union
Drug Overview: apalutamide

Drug Overview: apalutamide

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Apalutamide (Johnson&Johnson) is an orally available androgen signaling inhibitor. The drug exhibits high binding affinity to the ligand-binding domain of androgen receptor (AR) and subsequently ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: ipatasertib

Drug Overview: ipatasertib

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Ipatasertib (Roche) is a highly selective, ATP-competitive Akt inhibitor that preferentially targets active, phosphorylated Akt. Akt is dysregulated in a number of malignancies through loss ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on